Source comparison
IGF-1 LR3 Results After 1 Month: Expected vs Measured Comparison
Lean Mass Gain 5–8 kg in 4 weeks 1.5–3 kg (daily dosing, 50–80 mcg) Marketing claims conflate water retention with contractile tissue. Actual myofibrillar protein accretion is slower and requires structured training stimulus. Recovery Time 'Cuts soreness by 70
This comparison does not assign a generated winner or score.
- Lean Mass Gain
- 5–8 kg in 4 weeks
- 1.5–3 kg (daily dosing, 50–80 mcg)
- Marketing claims conflate water retention with contractile tissue. Actual myofibrillar protein accretion is slower and requires structured training stimulus.
- Recovery Time
- 'Cuts soreness by 70%'
- DOMS duration reduced by 24–48 hours; CK clearance accelerated by 30–40%
- Soreness reduction is measurable but modest. The primary benefit is faster restoration of force production, not elimination of post-exercise discomfort.
- Visible Muscle Fullness
- 'Immediate pump effect'
- Intramuscular glycogen increases 15–25% within 2 weeks; cell volumization detectable via ultrasound
- Glycogen supercompensation and increased intracellular water create measurable volume increases, but these are not permanent structural changes.
- Fat Loss
- 'Simultaneous recomposition'
- No direct lipolytic effect; nutrient partitioning may reduce fat gain during caloric surplus
- IGF-1 LR3 does not burn fat. It improves where calories are stored (muscle vs adipose), but this requires caloric control and training.
- Strength Gains
- 'Rapid performance boost'
- Indirect strength improvements via enhanced recovery and training volume tolerance
- Strength increases result from accumulated training volume enabled by faster recovery. Not acute performance enhancement.
- Side Effects
- 'Minimal if dosed correctly'
- Hypoglycemia risk in 10–15% of users; transient joint discomfort in 5–10%; rare reports of organ enlargement at sustained high doses
- Side effects are dose-dependent and underreported in marketing materials. Glucose monitoring is essential during titration.